TAKE Solutions Ltd. Enabling Business Efficiencies Corporate - - PowerPoint PPT Presentation

Corporate Presentation

TAKE Solutions Ltd.

Enabling Business Efficiencies

TAKE: Technology, Analytics & Knowledge for the Enterprise

2

Contents

 TAKE – At A Glance  Business Model & Market Potential  Competencies

− Life Sciences − Supply Chain Management

 Financials  Growth Strategies & Key TAKEaways  Appendix

3

TAKE Solutions – At A Glance

 Headquartered in Chennai, India, TAKE Solutions Ltd.

delivers technology, services and expert advice in Life Sciences and Supply Chain Management domains

 Strong presence in US, Europe and Middle East Asia: US

contributes approx. 2/3 of revenue

 CMMi Level 5 accredited company  Recognitions:

• TAKE Solutions receives SDCE 100 Award for Third

Consecutive Year

• TAKE is ranked Leader in the life science R&D IT
• utsourcing and Drug Safety market by IDC, a premier

global provider of market intelligence and advisory services IT markets

• Ranked first by a premier global analyst firm, for

industry expertise and overall customer satisfaction in Life Sciences domain

• “Editors’ Pick” Distinction by Consumer Goods

Technology Magazine

 We serve 410+ clients through 14 offices globally

with 1,100+ employees

 Life Sciences: Celgene, Eisai, Johnson & Johnson,

Merck, Neuromed, Novartis, Pfizer, Roche, Sanofi Aventis

 SCM: Applied Materials, Alcoa, GE Group,

Honeywell, Panasonic, ITC, Pepsi, Transocean, Xerox

About TAKE Marquee Clients Financials

 FY14 Revenue : INR 8,217 million  FY14 Net Profit: INR 580 million

2,500 5,000 7,500 10,000 FY10 FY11 FY12 FY13 FY14 INR million Revenue Net Profit

4

Global Footprint

Chennai, India Austin, TX Philadelphia, PA Muscat, Oman Princeton, NJ

TAKE Solutions Inc. 502 Carnegie Center, Suite 100, Princeton, NJ

USA HQ

TAKE Solutions Ltd. No.8B, Adyar Club Gate Road, Chennai - 600028, India

Global HQ

Riyadh, Jeddah & Al-Khobar Saudi Arabia Dubai, UAE

Strong Presence in the US, Middle East Asia and Europe

Hampshire, UK

TAKE Solutions LLP Shriram "The Gateway SEZ", Perungalathur, Chennai, India

Global Delivery Center

Singapore Abraq Khaitan, Kuwait

5

Recognitions and Partnerships



2014: Ranked 2nd at Asia‘s Best Employer Brand Awards, Singapore.



CMMi Level 5



2013: SDCE 100 Award for Third Consecutive Year



2013: 7th Employer Branding Award for Excellence in Training



2013: IDC ranked TAKE as Leader in the life science Drug Safety Services market based on our ddemonstrated delivery experience, deep understanding of drug safety processes & platforms and deep strategic drug safety expertise



2011: IDC, a global market intelligence firm, ranked TAKE as Leader in the life science R&D IT outsourcing market based

• n the company’s capabilities and future strategies aligned

with what customers will require in three to five years



2011 Supply & Demand Chain Executive 100 list



2010: A premier global analyst firm recognized and ranked TAKE, first among large system integrators for industry expertise & overall customer satisfaction in the Life Sciences Domain



2010 “Editors’ Pick” Distinction by Consumer Goods Technology Magazine



Global Logistics & Supply Chain Strategies 2010: 100 Great Supply Chain Partners List  Oracle Gold Partner  SAP Business Objects Gold Partner  Microsoft BIO IT alliance Partner  CDISC Solutions Partner  Microsoft’s Digital Pharma Initiative  Microsoft High Impact Gold partner  Sparta Systems  Generis

Certifications & Accreditation Alliances and Partnerships

Business Model & Market Potential

7

TAKE Solutions – Business Model

DOMAIN

Supply Chain Management & Life Sciences

TECHNOLOGY

Service Oriented Architecture (SOA) Cloud Computing Virtualization

DELIVERY model REVENUE model

SaaS On Premise Business Services



Embedded / RFID / Mobile Licenses Maintenance

TRANSACTIONS / SUBSCRIPTIONS

Services

    

8

TAKE Solutions – Business Model

 Balanced: Well distributed across two key verticals - niche offerings addressing multiple

end user industries

 Wide Portfolio of Offerings: Solutions to address customer needs - Solutions delivered

as business services, products and SaaS

 Diversified Customer Base: Portfolio of solutions to address customer size - focused

approach to large & mid-market customer segment and wider approach to SME segment

 Scalable: Platform agnostic solutions to enhance addressable markets and strategic

partnerships to drive penetration in areas of specialization

 Diversified Revenue Streams: Income from subscription, licensing, royalties, services and

AMC leading to a mix of annuity and non annuity revenues

9

Total Addressable Market

1.0 8.0 40.0 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 SaaS On Premise Business Services USD billion 5.7 10.2 0.0 2.0 4.0 6.0 8.0 10.0 12.0 Pre - Approval Post- Approval USD billion

Supply Chain Management Life Sciences

Domain Competency Life Sciences

11

Integrated Solutions & Services

12

Software products - Life Sciences

Clinical Regulatory Safety

Regulatory Submissions SPL/PLR PPM Safety eCTD Clinical Development Bio Statistical Programming TRMS SAS - Bio Statistics Framework eTMF CDISC Accelerators DMS

Oracle Life Sciences CTMS, EDC, CDMS, LSH/CDR Argus Safety AERS

13

Customer A Therapeutic Area 1 Indication A Indication B Phase1 Study I Phase2 Study 1 Therapeutic Area 2 Indication C Customer B Therapeutic Area 1 Indication D Indication E Phase1 Study 1 Study 1 Study 1 Phase2 Study 1 Study 1 Study 1 Therapeutic Area 2 Customer C Therapeutic Area 1 Customer D Therapeutic Area 1

Established customer relationships; scalable revenue model Technology + business services

TLFs, Biostatistics, SDTM, ADaM, ISS/ISE, DMCs, SAP, EAC, NDAs Increasing customer base Multiplying revenues

14

TAKE Life Sciences - Differentiators

 Unique combination of deep domain expertise and technical skills  Market penetration across

• Bio-pharmaceutical (branded & generic)
• Medical device
• CROs

 Mature infrastructure across USA and APAC

• People
• Process
• Infrastructure – SAS 70* compliant, validated data center

 Strategic partnerships with Oracle and Liquent  TAKE’s differentiated approach to markets

• Large and mid-market segment : Functional Service Provider
• Small and medium segment

: Full Service Provider

* SAS 70 (the Statement on Auditing Standards No. 70) defines the standards an auditor must employ in order to assess the contracted internal controls of a service organization. Service organizations, such as hosted data centers, insurance claims processors and credit processing companies, provide outsourcing services that affect the operation of the contracting enterprise.

15

TAKE Life Sciences - Strategy

• Broaden and deepen TAKE LS’ engagements with existing and potential clients by retaining and promoting existing and new portfolio of

solutions in clinical, regulatory, safety and content management to obtain new and/or larger contracts from its clients.

• In this direction, TAKE LS is also striving to become an important member of FIPNET community which enables it to work effectively together

with all its clients, pharmaceutical clients, suppliers, partners and regulators. Enlarge Clients’ Portfolio 1

• Commit its resources to focus on US and European clients, ensuring it is at the forefront of regulatory and market developments on multiple

platforms.

• Communicate and showcase its abilities to these clients in order to win projects related to LS process outsourcing and consulting.

Focus on US and European clients 2

• Leverage on its partners to educate pharmaceutical companies on TAKE LS’ capabilities, for example, in relation to the partners’ platform (e.g.

Oracle) to increase the usage of TAKE LS’ consulting and outsourcing offerings and expand its clientele base. Leverage on Partnerships 3

• Focus on increasing its offerings which can be monetised across delivery platforms e.g. products, services offered over SaaS platforms. These
• fferings may be developed inhouse or acquired through mergers and acquisitions.
• Enable all offerings to be device agnostic, platform and browser agnostic, to achieve scalability.

Focus on the Balanced Offering Mix 4

16

TAKE assessed as a LEADER in Life Sciences

Source: 1. IDC MarketScape: Worldwide Life Science R&D IT Outsourcing 2011 Vendor Assessment, August 2011

• 2. IDC MarketScape: Worldwide Life Science Drug Safety Services 2013 Vendor Assessment
• Capabilities: Evaluated on current capabilities and how well aligned it is to customer needs
• Strategies: Indicates how well the company’s future strategy aligns with what customers will require in three to five

years

Worldwide Life Science R&D IT Outsourcing 2011 Vendor Assessment Worldwide Life Science Drug Safety Services 2013 Vendor Assessment

17

Customer Profiles –Market Potential

Pharmaceutic al Biotechnology Consumer Health Animal Health Crop Science/Agroc hemicals Medical Devices Dietary Supplements Cosmetics Tobacco Generics Turnover > $100m 744 172 63 53 116 128 72 60 46 44 Turnover > $250m 476 123 53 44 100 99 56 52 40 40 Turnover > $500m 351 98 41 38 84 81 43 45 35 32 Turnover > $1b 257 88 34 27 71 60 36 35 29 22 257 88 34 27 71 60 36 35 29 22 351 98 41 38 84 81 43 45 35 32 476 123 53 44 100 99 56 52 40 40 744 172 63 53 116 128 72 60 46 44 200 400 600 800 1000 1200 1400 1600 1800 2000 Number of companies Customer/prospect type

Number of customers/prospects by type

18

Geographical spread of customers/prospects

North America Europe Africa Asia Australasia South America Generics 49 17 2 13 1 Tobacco 48 13 9 2 Cosmetics 175 1270 3 661 5 Dietary Supplements 150 23 2 34 1 1 Medical Devices 285 79 16 1 Crop Science/Agrochemicals 166 47 2 104 6 30 Animal Health 120 335 95 3 Consumer Health 83 27 2 20 1 Biotechnology 587 162 34 8 Pharmaceutical 4018 3757 33 3139 107 185 1000 2000 3000 4000 5000 6000 7000 Number of customers/prospects Geography

Customers/prospects by geography

19

Diverse Customer Base : Life Sciences

Bio-Tech CROs / Academic Pharma Generics / OTC Devices

We serve 7 of top 10 global pharmaceutical companies

Domain Competency Supply Chain Management

21

TAKE SCM Offerings

Overview

• Provides solutions and services catering to four sub-areas of SCM requirements:
• Enterprise Mobility & Auto ID: To track raw material movement and automate transactions taking place in warehouses, on docks, shop floors

and in-transit

• Value Chain Collaboration: To collaborate with suppliers, contract manufacturers, distributors and retailers by providing a public ecosystem or a

private network of trading-partners

• Supply-Chain Execution & Analytics: To streamline the process of material management and inventory control while monitoring and managing

supply-chain performance

• Caters to various industries such as Aerospace and Defense, Automotive, Consumer, Oil and Gas, Pharmaceuticals, Telecommunications etc

Product footprint

Enterprise mobility and WM Enabling efficient data collection and guided operations Supply chain collaboration Streamlining collaborative business process orchestration Professional services Delivering a powerful combination

• f industry and technology expertise

Oracle Data Collection and Warehouse Automation Mobile Sales & Route Delivery Barcode & RFID Management and Compliance Clinical Information Systems Contract Manufacturing Collaboration 3PL and Drop Ship Collaboration Vendor Managed Inventory Demand Collaboration & Purchasing Collaboration Request for Quote Collaboration Quality Collaboration E-Invoice & AP Automation Ship Confirmation Collaboration Oracle MSCA and WMS Implementation Supplier Onboarding/Enablement Oracle Advanced Supply Chain Planning Returns Management Supplier Collaboration Analytics

22

Business Services

Spend Analytics Supplier Performance Supplier Selection Contract Administration Consulting & Insight NAFTA Compliance AP automation Catalog Services Supplier Enablement Invoice Processing Requisition Processing Reverse Engineering Value Engineering Prototyping Simulation & Testing Design Drawing & Documentation

Sourcing Support Sourcing

• Engg. Services

Procurement Operations

23

Business Strategy

 Niche Focus – Do what we are good in, highly profitable and which creates

shareholder value

 We will focus on:

 Enterprise mobility products  Collaboration Products  Engineering services

 Geographically we will focus on US and few parts of Middle East Asia

24

Diverse Customer Base - Global SCM Customers

Pharma & Medical Industrial Products/ Services Consumer Products High Tech FMCG / Food Oil & Gas

Financial Highlights

26

Growth Trends

3,664 5,063 7,188 8,386 8,217 3,000 6,000 9,000 FY 2010 FY 2011 FY2012 FY 2013 FY 2014 INR mn

Total Revenues

324 700 856 795 580 300 600 900 FY 2010 FY 2011 FY2012 FY 2013 FY 2014 INR mn

Net Profit

53% 49% 44% 42% 39% 41% 47% 51% 50% 53% 0% 20% 40% 60% 80% 100% FY 2010 FY 2011 FY2012 FY 2013 FY 2014

Revenue by Vertical

SCM Life Sciences Others 63% 65% 63% 57% 60% 37% 33% 31% 36% 35% 0% 20% 40% 60% 80% 100% FY 2010 FY 2011 FY2012 FY 2013 FY 2014

Revenue by Geography

United States Asia RoW

27

Quarterly Growth Trends

2,117 2,071 1,953 1,957 2,109 2,123 1,967 1,615 1,690

• 2.8%
• 2.2%
• 5.7%

0.2% 7.7% 0.7%

• 7.4%
• 17.9%

4.6%

• 20.0%
• 15.0%
• 10.0%
• 5.0%

0.0% 5.0% 10.0% 15.0% 20.0% 500 1,000 1,500 2,000 2,500 Q2 FY13 Q3 FY13 Q4 FY13 Q1 FY14 Q2 FY14 Q3 FY14 Q4 FY14 Q1 FY15 Q2 FY15 INR million

Revenue

Revenue Growth q-o-q (%) 416 383 368 353 382 386 352 313 328 211 178 154 132 151 167 129 130 134 19.7% 18.5% 18.8% 18.0% 18.1% 18.2% 17.9% 19.4% 19.4% 10.0% 8.6% 7.9% 6.8% 7.2% 7.9% 6.6% 8.0% 7.9% 0% 5% 10% 15% 20% 25% 100 200 300 400 500 Q2 FY13 Q3 FY13 Q4 FY13 Q1 FY14 Q2 FY14 Q3 FY14 Q4 FY14 Q1 FY15 Q2 FY15 INR million

Profitability

• Op. EBITDA

Net Profit

• Op. EBITDA Margin (%)

Net Margin (%)

28

Share Holding Pattern

Category No of Shares % of Total Q-o-Q Change (%)

Promoter & Promoter Group 83,672,200 68.4% 0.00% Public Shareholding

• Institutions

DIIs

• 0.0%

0.00% FIIs 1,947,506 1.6%

• 0.05%

Trust 2,765,422 2.3% 0.00%

• Non Institutions

Bodies Corporate 13,576,764 11.1% 0.11% Retail/Others 20,438,108 16.7%

• 0.06%

TOTAL 122,400,000 100.0%

Shareholding Patterns (Sept 30, 2014)

Promoter & Promoter Group 68.4% FIIs 1.6% Trust 2.3% Bodies Corporate 11.1% Retail/Others 16.7%

Growth Strategies And Key TAKEaways

30

Key Growth Strategies

• Broaden and deepen TAKE’s engagements with existing and potential clients by retaining and promoting existing and new portfolio of

solutions in clinical, regulatory, safety and content management to obtain new and/or larger contracts from its clients.

• In this direction, TAKE LS is also striving to become an important member of FIPNET community which enables it to work effectively

together with all its clients, pharmaceutical clients, suppliers, partners and regulators. Enlarge Clients’ Portfolio 2

• Commit its resources to focus on US and European clients, ensuring it is at the forefront of regulatory and market developments on

multiple platforms.

• Communicate and showcase its abilities to these clients in order to win projects related to rocess outsourcing and consulting.

Focus on US and European clients 3

• Leverage on its partners to educate pharmaceutical companies on TAKE’s capabilities, for example, in relation to the partners’ platform

(e.g. Oracle) to increase the usage of TAKE LS’ consulting and outsourcing offerings and expand its clientele base. Leverage on partnerships 4

• Increase its offerings which can be monetised across delivery platforms e.g. products, services offered over SaaS platforms. These
• fferings may be developed in-house or acquired through mergers and acquisitions.
• Enable all offerings to be device, platform and browser agnostic, to achieve scalability.

Efficient and scalable delivery platforms 5

• 1. Fully Integrated Pharmaceutical Network
• TAKE will focus on Life Sciences business in the future due to its unique positioning that TAKE has achieved over the years , which is not

easy to replicate Focus on Life Sciences Business 1

31

Key TAKEaways

 Strong fundamentals

• Domain expertise
• Marquee client list
• Niche player operating in niche segments
• Strong Portfolio of products and services

 Growth momentum

• Traction in Life Sciences vertical
• Sustained growth in order book providing visibility

 Improving financials

• Traction in revenue and expansion in margins
• Improvement in key operating metrics and profitability ratios

32

Appendix

Acronyms Meanings

CTMS Clinical Trial Management System EDC Electronic Data Capture CDMS Clinical Data Management System eDMS Electronic Document Management System eSub Electronic Submissions CDR Clinical Data Repository LSH Life Sciences Hub PV Pharmacovigilance IND Investigational New Drug CTA Clinical Trial Authorization NDA New Drug Application PaaS Platform as a Service ETL Extract Transform and Load PO collaboration Purchase Order Collaboration AP automation Accounts Payables Automation

THANK YOU

Disclaimer:

This presentation has been prepared by TAKE Solutions Ltd. (the “Company”) solely for your information and for your use and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization or firm) or published in whole or in part, for any purpose. By attending this presentation, you are agreeing to be bound by the foregoing restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials. Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT including factors which may affect our cost advantage, wage increases, our ability to attract and retain highly skilled professionals, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in Supply Chain Management (SCM) & Life Sciences (LS), disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. TAKE does not undertake to update any forward- looking statement that may be made from time to time by or on behalf of the company.

TAKE: Technology, Analytics & Knowledge for the Enterprise

For further information, please contact: Sachin Garg sachingarg@takesolutions.com